RumiViro has developed a transformative process for screening and testing therapeutics for infectious diseases. Our technology is a powerful high-throughput platform to generate miniaturized synthetic tissues that mimic lungs that are highly susceptible to viral infection. We have an unparalleled ability to track viral infection in thousands of synthetic mini lungs at a time. This company is an evolution of a collaboration between Dr. Ali Brivanlou and Nobel-prize winner Dr. Charles Rice, both at Rockefeller University, who worked together to combine the disciplines of stem cell biology and virology to tackle COVID-19. This platform has been used to mimic the entire lifecycle of SARS-CoV-2 infection and the lung pathology observed in COVID-19 . We intend to exploit our interdisciplinary approach to drug discovery and merge state of the art technologies to move forward quickly toward therapeutic discoveries for COVID-19 and other infectious diseases.